-

Ypsomed Holding AG (YPSN) Product Pipeline Analysis Report 2025: Self-Injection and Infusion Systems Portfolio - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Ypsomed Holding AG (YPSN) - Product Pipeline Analysis, 2025 Update" company profile has been added to ResearchAndMarkets.com's offering.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

Ypsomed Holding AG (Ypsomed) is a medical device company. It designs, develops, and manufactures injection and infusion systems for self-medication and offers related services. The company's products find application in the treatment of diabetes, infertility, growth disorders and various other clinical indications. Ypsomed's product portfolio includes autoinjectors, dual chamber pens, and pen injectors.

The company also provides services ranging from design and development projects, flexible prototyping, human factors engineering, monitoring services, therapy management and IP landscape management to manufacturing and assembly infrastructure and registration support. Ypsomed offers solutions to physicians, and pharmaceutical and biotechnology companies. The company has operations in Switzerland, Europe, and North America, among others. Ypsomed is headquartered in Burgdorf, Switzerland.

The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Ypsomed Holding AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed descriptions of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.

Ypsomed Holding AG, Recent Developments

  • Sep 11, 2025: Ypsomed Receives FDA 510(K) Clearance For SmartPilot YpsoMate NS-A2.25
  • Sep 02, 2025: Sharp Invests $20 Million in Autoinjector & Pen Assembly Lines to Meet Rising Demand for Injectables
  • Sep 01, 2025: Ypsomed Receives FDA Clearance for SmartPilot
  • Jul 01, 2025: Global First Dual GCG/GLP-1 Receptor Agonist for the Treatment of Obesity Launched in an Ypsomed Autoinjector in China
  • Jun 27, 2025: Ypsomed opens production site in China
  • Apr 07, 2025: Ypsomed and Sidekick Health Launch a Collaborative Digital Health Solution for Obesity Management
  • Mar 18, 2025: Ypsomed and CamDiab launch mylife Loop on iOS
  • Nov 13, 2024: Ypsomed significantly increases sales and decides to initiate the sale of Diabetes Care
  • Oct 24, 2024: Ypsomed and BD to Enhance High-Viscosity Drug Delivery
  • Oct 23, 2024: Ypsomed and BD collaborate to advance self-injection systems for high viscosity biologics

Key Topics Covered:

  • Ypsomed Holding AG Company Overview
  • Ypsomed Holding AG Company Snapshot
  • Ypsomed Holding AG Pipeline Products and Ongoing Clinical Trials Overview
  • Ypsomed Holding AG - Pipeline Analysis Overview
  • Business Description
  • Ypsomed Holding AG - Key Facts
  • Ypsomed Holding AG - Major Products and Services
  • Ypsomed Holding AG Pipeline Products by Development Stage
  • Ypsomed Holding AG Ongoing Clinical Trials by Trial Status
  • Ypsomed Holding AG Pipeline Products Overview
  • mylife Loop
  • mylife Loop Product Overview
  • mylife Loop Clinical Trial
  • mylife YpsoPump
  • mylife YpsoPump Product Overview
  • mylife YpsoPump Clinical Trial
  • mylife YpsoPump 2.0 With Integrated CGM
  • mylife YpsoPump 2.0 With Integrated CGM Product Overview
  • UnoPen Zero
  • UnoPen Zero Product Overview
  • YpsoDose
  • YpsoDose Product Overview
  • YpsoDose Zero
  • YpsoDose Zero Product Overview
  • YpsoMate Zero 2.25 Pro
  • YpsoMate Zero 2.25 Pro Product Overview
  • YpsoMate Zero On
  • YpsoMate Zero On Product Overview
  • YpsoPod
  • YpsoPod Product Overview
  • Ypsomed Holding AG - Key Competitors
  • Ypsomed Holding AG - Key Employees
  • Ypsomed Holding AG - Key Employee Biographies
  • Ypsomed Holding AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • Appendix

For more information about this company profile visit https://www.researchandmarkets.com/r/43pquj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Hexabromocyclododecane (CAS 25637-99-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Hexabromocyclododecane (CAS 25637-99-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. This report on Hexabromocyclododecane provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a v...

Commercial Gas Rice Cookers Market Report 2026: Revenues Set to Reach $2 Billion by 2032 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Commercial Gas Rice Cookers Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Commercial Gas Rice Cookers Market is experiencing significant growth, evolving from USD 1.28 billion in 2025 to an anticipated USD 2.00 billion by 2032, driven by a CAGR of 6.52%. This market research report provides a comprehensive analysis of the commercial gas rice cooker sector, highlighting key drivers like foodservice efficiency, industria...

Artemisinin Combination Therapy Market to Grow by $194 Million During 2026-2032 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Artemisinin Combination Therapy Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Artemisinin Combination Therapy (ACT) market exemplifies dynamic growth and promising potential in the treatment of malaria. Expected to increase from USD 386.40 million in 2025 to USD 608.26 million by 2032, supported by a steady CAGR of 6.69%, this market highlights the evolving landscape for modern antimalarial solutions. At the core of AC...
Back to Newsroom